Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration

News provided by

Clearmind Medicine

March 8, 2022

The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties.

TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0)

(“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced a Collaboration agreement (the “Collaboration”) with SciSparc Ltd. (NASDAQ: SPRC).

The two companies will explore the potential for the creation of innovative compounds in the psychedelic area. The Collaboration will address, inter alia, examining the benefit of integrating the core technologies of each company by combining molecules from their respective development pipelines. The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties.

“Our aim is to develop innovative, effective and safe psychedelic-derived therapeutics that could transform the mental health pharmaceutical market,” said Clearmind CEO Adi Zuloff-Shani. “Clearmind has established a number of R&D partnerships, in order to continue strengthening its IP portfolio, including with leading academic, research and medical institutions. We’re excited about the Collaboration with SciSparc, which we consider symbiotic, and expecting to reveal more details about the science behind the Collaboration soon.”

The Collaboration is a “Related Party Transaction” (as such term is defined in “Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions” (the “Instrument”) as certain directors and officers of the Company are also or have been directors and officers of SciSparc Ltd. The Company will comply with the Instrument but expects to rely on the exemptions available in Sections 5.5 (a) and 5.7 (a) of the Instrument as they relate to the Collaboration.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company’s intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol "CMNDF".

About SciSparc (NASDAQ:SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of obstructive sleep apnea and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

For further information, please contact:

Investor Relations

Telephone: (604) 260-1566

General Inquiries


This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.